Caribou Biosciences, Inc.
CRBU evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRBU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRBU
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary CRISPR chRDNA genome-editing technology, with a lead candidate vispa-cel in a planned pivotal phase 3 trial for relapsed/refractory large B-cell lymphoma.
Key risk: Clinical trial and regulatory risks
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Caribou Biosciences, Inc..
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary CRISPR chRDNA genome-editing technology, with a lead candidate vispa-cel in a planned pivotal phase 3 trial for relapsed/refractory large B-cell lymphoma.
- Caribou is focused on allogeneic CAR-T cell therapies, leveraging its CRISPR chRDNA genome-editing platform to create off-the-shelf cell therapies [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash and equivalents of $26.2M, total revenue of $1.5M, and a net loss of -$24.3M [sec].
- The lead product candidate, vispa-cel, is being advanced toward a planned pivotal phase 3 clinical trial (ANTLER-3) in 2L LBCL CD19-naïve patients [sec · filed 2025-11-03].
- The company has an accumulated deficit and expects operating losses to continue as it progresses clinical trials and development activities [sec_mda · as of 2026-08-13].
- Caribou's future capital requirements depend on factors including clinical trial costs, regulatory timelines, and potential in-licensing of intellectual property [sec_mda · as of 2025-08-12].
What works
- Caribou's proprietary CRISPR chRDNA genome-editing technology may enable the development of differentiated allogeneic CAR-T therapies with a competitive edge [sec_mda · as of 2026-08-13].
- The company is advancing vispa-cel toward a pivotal phase 3 trial, indicating progress in clinical development for a large patient population (2L LBCL) [sec · filed 2025-11-03].
- Caribou has a second product candidate, CB-011, in clinical development, diversifying its pipeline [sec_mda · as of 2026-08-13].
What to weigh
- Caribou has a history of net losses and negative cash flows, with a net loss of $24.3M for the quarter ended June 30, 2026 [sec].
- The company may never generate revenue or material net cash inflows from product commercialization, as it has no approved products and faces significant regulatory and clinical risks [sec_mda · as of 2026-08-13].
- Cash and equivalents of $26.2M as of June 30, 2026, may be insufficient to fund all planned clinical trials and operations without additional financing [sec_mda · as of 2026-08-13].
- The company's success depends on acceptance of its CRISPR chRDNA technology and ability to avoid infringing third-party intellectual property rights [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Caribou is advancing vispa-cel toward a pivotal phase 3 trial in 2L LBCL.
“expected design, protocol, and timing of initiation of the pivotal phase 3 clinical trial for vispa-cel in 2L LBCL CD19-naïve patients”
SEC filings · November 3, 2025
The company may never achieve regulatory approval or generate product revenue.
“if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we may obtain marketing approval”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial and regulatory risks — Uncertainties in trial initiation, cost, timing, and results may delay or prevent approval of vispa-cel and CB-011 [sec · filed 2025-11-03].
- Financing and cash runway — With $26.2M cash as of June 30, 2026, the company may need additional funding to complete planned trials and operations [sec_mda · as of 2026-08-13].
- Technology and IP dependence — Success relies on acceptance of CRISPR chRDNA technology and avoiding infringement of third-party patents [sec_mda · as of 2026-08-13].
- No approved products or revenue — The company has no marketed products and may never generate material revenue from product sales [sec_mda · as of 2026-08-13].
What to watch
- Initiation and enrollment progress of the pivotal phase 3 trial (ANTLER-3) for vispa-cel in 2L LBCL [sec · filed 2025-11-03].
- Updates on clinical data for CB-011 and any dose expansion plans [sec · filed 2025-11-03].
- Cash runway and any additional financing activities, given the $26.2M cash position as of June 30, 2026 [sec].
- Regulatory interactions and milestones, including potential FDA feedback on vispa-cel's development path [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Caribou Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Caribou Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
14.4 months
D/E 0.46 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
131
Total value held
$60.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,534,456 | $14.3M |
| renaissance technologies llc | 2,590,497 | $4.9M |
| blackrock, inc. | 2,143,085 | $4.1M |
| two sigma investments, lp | 1,759,934 | $3.3M |
| bank of america corp /de/ | 1,297,167 | $2.5M |
| marshall wace, llp | 1,205,668 | $2.3M |
| millennium management llc | 1,074,421 | $2.0M |
| susquehanna international group, llp | 1,047,203 | $2.0M |
| geode capital management, llc | 1,017,959 | $1.9M |
| pfm health sciences, lp | 957,787 | $1.8M |
Showing top 10 of 131 institutional holders of Caribou Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.5%
- Days to cover
- 4.9
- Shares short
- 7,123,813
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRBU short interestGovernance
Frequently asked questions
What is the AI investment thesis for Caribou Biosciences, Inc.?
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary CRISPR chRDNA genome-editing technology, with a lead candidate vispa-cel in a planned pivotal phase 3 trial for relapsed/refractory large B-cell lymphoma.
What is Caribou Biosciences, Inc.'s lead drug candidate?
Caribou Biosciences, Inc.'s most advanced tracked candidate is CB-010 (Phase 1) for second-line relapsed or refractory large B cell lymphoma (r/r LBCL).
Who is the CEO of Caribou Biosciences, Inc.?
Dr. Rachel E. Haurwitz Ph.D. is the chief executive officer of Caribou Biosciences, Inc. (CRBU).
Where is Caribou Biosciences, Inc. headquartered?
Caribou Biosciences, Inc. (CRBU) is headquartered in Berkeley, CA, United States.
What therapeutic areas does Caribou Biosciences, Inc. focus on?
Caribou Biosciences, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.